COMMUNIQUÉS West-GlobeNewswire

FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants

14/02/2018 - 16:45

FIT Biotech Oy Company release February 14, 2018 at 5:45 pm EET FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants On December 22, 2017, the Board of Directors of FIT Biotech [...]

The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day

14/02/2018 - 16:35

WASHINGTON, D.C., Feb. 14, 2018 (GLOBE NEWSWIRE) -- The Alliance for Regenerative Medicine (ARM) today announced its annual Cell & Gene Therapy Investor Day will take place April 17, 2018 in New York City. This [...]

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

14/02/2018 - 16:31

FIT Biotech Oy Company release February 14, 2018 at 5:30 PM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 [...]

Emerald Health Therapeutics Closes $18 Million Prospectus Sale

14/02/2018 - 15:52

VICTORIA, British Columbia, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) ("Emerald" or the “Company”) has closed its prospectus sale (the “Offering”) to a single Canadian [...]

Tauriga Sciences Inc. Gains Exposure to Electric Vehicle Infrastructure Market Segment Through Strategic $191,250 USD Transaction

14/02/2018 - 15:40

NEW YORK, NY, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), engaged in building its business through the development, distribution, and licensing of proprietary [...]

Teligent, Inc. Announces FDA Approval of Betamethasone Dipropionate Lotion USP (Augmented), 0.05%

14/02/2018 - 15:31

BUENA, N.J., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT ), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug [...]

Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125

14/02/2018 - 15:05

-- Trial to Enroll Approximately 15 Patients with Psoriasis -- Top-Line Results Expected in Third Quarter of 2018 WESTLAKE VILLAGE, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA [...]

Patient Home Monitoring Announces Plans to Change Name; Appoints New CFO in Advance of Acquisition Strategy

14/02/2018 - 15:00

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN. CINCINNATI, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Patient Home [...]

Oncobiologics Reports First Quarter Fiscal Year 2018 Results

14/02/2018 - 15:00

CRANBURY, N.J., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ: ONS ) today reported financial results and business highlights for its first fiscal quarter ended December 31, 2017. Oncobiologics had a net [...]

Burcon Announces Completion of Rights Offering

14/02/2018 - 14:32

VANCOUVER, British Columbia, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Burcon NutraScience Corporation (TSX: BU ) (NASDAQ: BUR ) (" Burcon " or the " Company ") is pleased to announce the completion of its rights offering (the [...]

MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients

14/02/2018 - 14:30

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK ), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable [...]

Scythian Biosciences Corp. Announces Approval for Listing on the Nasdaq Capital Markets under Symbol “SCYB” and Ringing of the Nasdaq Closing Bell

14/02/2018 - 14:30

TORONTO, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the “ Company ” or “ Scythian ”) (TSXV:SCYB) (Frankfurt: 9SB ) (OTCQB:SCCYF) is pleased to announce that the Company has received approval from the [...]

Agritek Holdings, Inc. Announces Licensing Deal With Pre-ICO Manufacturing Facility in California for Company’s Roll Out of California Premiums Exclusive Pre-Roll Brand

14/02/2018 - 14:30

LOS ANGELES, CA, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Agritek Holdings, Inc. (OTCQB: AGTK) www.AgritekHoldings.com , a fully integrated, active cannabis real estate investor and branding consultant in the legal cannabis [...]

Imaging3’s Newly Appointed CEO, John Hollister, Reflects on his First 45 Days at The Company

14/02/2018 - 14:30

BURBANK, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Imaging3, Inc. (OTCQB:IGNG); I joined Imaging3, a development stage company in Burbank, California, to target disruptive technologies in the medical imaging industry [...]

Avinger Announces Pricing of $18 Million Underwritten Public Offering

14/02/2018 - 14:30

REDWOOD CITY, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ: AVGR ), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the pricing of an underwritten [...]

Avadel Pharmaceuticals Announces Pricing of $125.0 Million 4.50% Exchangeable Senior Notes due 2023

14/02/2018 - 14:27

DUBLIN, Ireland, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL ) (“Avadel” or “the Company”) today announced that its wholly-owned subsidiary, Avadel Finance Cayman Limited (the “Issuer”), [...]

Iovance Biotherapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference

14/02/2018 - 14:00

SAN CARLOS, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) [...]

Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer at 2018 Keystone Symposia on Emerging Cellular Therapies

14/02/2018 - 14:00

SAN DIEGO, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, presented preclinical [...]

Tauriga Sciences, Inc. Fully Repays $27,500 Face Value 8.00% Convertible Debenture Issued to Adar Bays, LLC for One Time Cash Payment of $39,312.78

14/02/2018 - 14:00

New York, NY, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTC PINK Current Tier: TAUG) ("Tauriga" or the "Company"), engaged in building business through the development, distribution, and licensing of [...]